Aclaris Therapeutics (ACRS) investor relations material

Executive summary

• Clinical-stage biopharma advancing novel small and large molecule candidates for immuno-inflammatory diseases using its KINect platform.

• Key pipeline assets include bosakitug (anti-TSLP mAb), ATI-2138 (ITK/JAK3 inhibitor), ATI-052 (bispecific antibody), and ATI-9494 (ITK/TXK inhibitor).

• Achieved positive Phase 1a SAD/MAD results for ATI-052, confirming best-in-class potency and extended dosing potential.

• Completed enrollment in Phase 2 trial of bosakitug for atopic dermatitis; top line results expected Q4 2026.

• Announced development strategy for ATI-2138 in lichen planus and presented strong Phase 2a results at AAD 2026.

Financial highlights

• Total revenue for Q1 2026 was $2.0 million, up from $1.5 million in Q1 2025, driven by higher contract research, licensing revenue, and royalties.

• Net loss for Q1 2026 was $19.8 million, compared to $15.1 million in Q1 2025, reflecting increased R&D and G&A expenses.

• R&D expenses rose to $15.7 million from $11.6 million year-over-year, mainly due to ATI-052 and ATI-9494 development.

• Cash, cash equivalents, and marketable securities totaled $190.8 million as of March 31, 2026, up from $151.4 million at year-end 2025.

• Operating cash outflow was $18.1 million for Q1 2026.

Outlook and guidance

• Sufficient liquidity to fund operations for more than 12 months from the reporting date, with cash runway projected through end of 2028.

• Anticipates continued net losses as clinical and preclinical programs advance; additional capital will be required for long-term strategy.

• Top-line data from key clinical trials, including ATI-052 and bosakitug, expected in late 2026.

• Phase 2b program for ATI-052 in asthma to begin Q4 2026; IND filing for ATI-9494 planned for H2 2026.